DDInter1595 DDInter832
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Rilpivirine {u} (Compound) binds {v} (Gene) CYP3A4
Rilpivirine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Rilpivirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Ranitidine
Rilpivirine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Rilpivirine (Compound) resembles Etravirine (Compound)
Rilpivirine (Compound) binds CYP3A4 (Gene)
Rilpivirine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Rilpivirine (Compound) causes Blood creatinine increased (Side Effect)
Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Rilpivirine may lead to a major life threatening interaction when taken with Lumacaftor
Rilpivirine may lead to a major life threatening interaction when taken with Ranitidine
Rilpivirine (Compound) resembles Pazopanib (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib